Biotech companies at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
28 biotech companies are at IDWeek 2026 — 46 presentations on the program and 11 with a booth in the exhibit hall. Most represented: Innoviva Specialty Therapeutics (3 on the program), AiCuris (3 on the program), Vaxcyte (2 on the program). 18 of them have their own page in this guide. As of Oct 16, 2026.
Topic
Top represented
Showing 1–11 of 28 organizations
| Organization | IDWeek 2026 Attendance |
|---|---|
Innoviva Specialty Therapeutics Waltham, MA | |
Innoviva subsidiary developing and selling critical care and infectious disease medicines, including an antibiotic for Acinetobacter infections and a septic shock vasopressor. | Booth Exhibiting at Booth 515 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Wed Oct 21 11:00am–12:00pm The Evolving Management of S. aureus Bacteremia: 2026 Updates and Emerging Evidence Antimicrobials, resistance and stewardship Poster Thu Oct 22 12:15pm–1:30pm Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right‑Sided Infective Endocarditis Using Model-Based Approaches Poster Sat Oct 24 12:15pm–1:30pm Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections Talk Sat Oct 24 2:15pm–2:30pm Zoliflodacin Maintains High Rates of Microbiologic Eradication of Urogenital Neisseria gonorrhoeae in Patients Co-infected with Chlamydia trachomatis Antimicrobials, resistance and stewardshipHIV, sexually transmitted infections and viral hepatitis |
AiCuris Wuppertal, Germany | |
German anti-infective drug developer behind letermovir and pritelivir, an antiviral for refractory herpes simplex infections. | Industry Fri Oct 23 8:48am–9:00am Pritelivir for refractory HSV infections in immunocompromised adults Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Poster Sat Oct 24 12:15pm–1:30pm AIC468, a Novel Antisense Oligonucleotide in Clinical Development for the Treatment of BKV in Kidney Transplant Recipients: Evidence of Broad BKV Strain Coverage and a Low Probability of Pre‑Existing Drug Resistance Poster Sat Oct 24 12:15pm–1:30pm Impact of Acid-Reducing Agents on the Pharmacokinetics of Pritelivir, a Novel Oral Herpes Simplex Virus (HSV) Helicase-Primase Inhibitor Poster Sat Oct 24 12:15pm–1:30pm Safety and Pharmacokinetics of AIC468, a Novel Antisense Oligonucleotide Targeting BK-Virus Transcripts, Following Multiple Dosing in Healthy Volunteers |
Vaxcyte San Carlos, CA | |
Vaccine company developing broader-coverage pneumococcal conjugate vaccines, led by VAX-31, a 31-valent candidate in Phase 3 trials. | Booth Exhibiting at Booth BS 16, BS 25 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 1:30pm–1:50pm Poster Sat Oct 24 12:15pm–1:30pm Design and Rationale of the Phase 3 OPUS-1, OPUS-2, and OPUS-3 Trials Evaluating a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults Poster Sat Oct 24 12:15pm–1:30pm Projected Public Health Impacts of PCV20, PCV21, and VAX-31, a 31-Valent Investigational Pneumococcal Conjugate Vaccine, in US Adults |
F2G Manchester, United Kingdom | |
Biotech developing olorofim, an oral antifungal from a new class, the orotomides, for invasive aspergillosis and other hard-to-treat mould infections. | Booth Exhibiting at Booth 1340 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Thu Oct 22 10:42am–10:54am Olorofim versus AmBisome®-Based Standard of Care (SOC) for Treatment of Invasive Aspergillosis (IA) in Patients for Whom a Mold-Active Azole Antifungal (MAA) is Inappropriate or Ineffective (OASIS): A Phase 3, Randomized, Controlled, Adjudicator-Blinded Non-Inferiority (NI) Trial (NCT05101187) Antimicrobials, resistance and stewardship Poster Sat Oct 24 12:15pm–1:30pm Health-Related Quality of Life in Patients with Invasive Fungal Infections with Limited or No Treatment Options: An Analysis of the Phase 2b Olorofim Trial Data |
Elion Therapeutics Boston, MA | |
Clinical-stage biotech developing turletricin, a once-weekly polyene antifungal designed to avoid kidney toxicity. | Talk Wed Oct 21 11:05am–12:30pm Poster Thu Oct 22 12:15pm–1:30pm Safety of Turletricin (EL219) in Phase 1 Single-Ascending (SAD) and Multiple-Ascending Dose (MAD)-Escalation and Renal Impairment (RI) Trials Industry Fri Oct 23 8:24am–8:36am Turletricin (EL219/SF001) a novel, once weekly, non-nephrotoxic polyene antifungal Antimicrobials, resistance and stewardship |
Evrys Bio Doylestown, PA | |
Biotech developing host-targeted small-molecule antivirals that act on the human enzyme sirtuin 2, starting with transplant-related viral infections. | Poster Thu Oct 22 12:15pm–1:30pm Host-Targeted Antiviral EV-100 Is Broadly Effective Against Four Major Classes of Opportunistic Viruses (Herpes, Polyoma-, Hepatic, and Respiratory Viruses) and May Therefore Be Suitable for Pan-Viral Prophylaxis or Preemptive Use Talk Fri Oct 23 12:30pm–12:35pm Host-Targeted Antiviral EV-100 Is Broadly Effective Against Four Major Classes of Opportunistic Viruses (Herpes, Polyoma-, Hepatic, and Respiratory Viruses) and May Therefore Be Suitable for Pan-Viral Prophylaxis or Preemptive Use Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Poster Sat Oct 24 12:15pm–1:30pm Human Sirtuin 2 (SIRT2) is an Epigenetic Small-Molecule Drug-Target for Functional Cure of Chronic Hepatitis B |
Chinese drug company developing HIV antiretrovirals, including the integrase inhibitor asuptegravir. | Poster Fri Oct 23 12:15pm–1:30pm Long-Term Viral Suppression and Cardiometabolic Benefits of Switching to Ainuovirine/Lamivudine/Tenofovir DF in Virologically Suppressed People with HIV-1: 192-Week Extended Results from the SPRINT Study Poster Sat Oct 24 12:15pm–1:30pm Pharmacokinetics, Predicted Antiviral Activity, and Safety of Single-Ascending-Dose Asuptegravir, A New-Generation Integrase Strand Transfer Inhibitor, in Healthy Adults: A Two-Period, Randomized, Placebo-Controlled Phase 1 Study Poster Sat Oct 24 12:15pm–1:30pm Viral Kinetics, Pharmacokinetics, And Exposure-Response Analysis of Monotherapy of Multiple Ascending Dose Asuptegravir, a New-Generation Integrase Strand Transfer Inhibitor, Followed by Combination with Emtricitabine And Tenofovir Alafenamide in Treatment-Naïve People Living with HIV-1: a Two-Period, Randomized, Placebo-Controlled Phase 1/2 Study. |
Model Medicines San Diego, CA | |
AI-driven drug discovery company developing MDL-001, an oral broad-spectrum antiviral aimed at respiratory viruses and chronic hepatitis. | Poster Thu Oct 22 12:15pm–1:30pm The RdRp Thumb-1 pocket is a Conserved Target for Broad-Spectrum Antiviral Development Poster Sat Oct 24 12:15pm–1:30pm Oral MDL-001 a Universal Direct Acting Antiviral for Influenza Like Illness(ILI): In Vivo Equivalence or Superiority to Oseltamivir, Nirmatrelvir and Remdesivir, In Vitro Superiority to Ribavirin Talk Sat Oct 24 3:30pm–3:45pm Oral MDL-001 a Universal Direct Acting Antiviral for Chronic Hepatitis: In Vivo Equivalence to Sofosbuvir, Single-Agent Activity Against HCV/HBV and HDV/HBV Coinfections. HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship |
Acurx Pharmaceuticals Staten Island, NY | |
Clinical-stage company developing a new class of antibiotics against bacteria that health agencies rank as priority pathogens. | Booth Exhibiting at Booth 620 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 10:30am–10:50am Novel Antibiotic for Both the Treatment and the Reduction of Recurrence of C. difficile Infection Antimicrobials, resistance and stewardship Industry Sat Oct 24 11:00am–11:20am Novel Antibiotic for Both the Treatment and the Reduction of Recurrence of C. difficile Infection Antimicrobials, resistance and stewardship |
Debiopharm Lausanne, Switzerland | |
Swiss biopharmaceutical company developing afabicin, an antibiotic that targets staphylococci. | Poster Sat Oct 24 12:15pm–1:30pm Clinical and Microbiological Response to Afabicin in a Phase 2 Clinical Trial in Patients with Bone and Joint Infections Caused by Staphylococcus spp. Poster Sat Oct 24 12:15pm–1:30pm Microbiota-Sparing Potential of Afabicin: Microbiome and Metabolomics Analysis of Stool Samples From Patients with BJI Treated with Afabicin for up to 6 Weeks |
TaiMed Biologics Taipei, Taiwan | |
Taiwanese biotech that developed ibalizumab (Trogarzo), an antibody for multidrug-resistant HIV, and is developing further HIV antibodies. | Poster Thu Oct 22 12:15pm–1:30pm TMB-365 and TMB-380: A potentially resistance repellant stand-alone maintenance bNAb regimen in suppressed people living with HIV-1 on combination antiretroviral therapy Talk Fri Oct 23 2:45pm–2:57pm Single-dose escalation study of TMB-365 in people living with HIV: safety, pharmacokinetics, and antiviral activity HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse IDWeek 2026 by
Organization type
Topic
- Antimicrobials, resistance and stewardship 420
- Vaccines 122
- Diagnostics and diagnostic stewardship 247
- HIV, sexually transmitted infections and viral hepatitis 256
- Infection prevention and healthcare epidemiology 292
- Transplant and immunocompromised hosts 173
- Respiratory infections and COVID-19 163
- Global and public health 211
Exhibit hall
Everyone
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction